MannKind's Afrezza Inhaled Insulin Approved for Children; Updated Label Provides New Dose Guidance for Adults
FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.